Skip to main content

Table 3 Comparison of clinical outcome on baseline and 6 months after implantation of P-MSCs

From: Report of a phase 1 clinical trial for safety assessment of human placental mesenchymal stem cells therapy in patients with critical limb ischemia (CLI)

Case

Cell dose

Walking distance

Rest pain

ABI

Vascular quality of life (questionnaire-6)

Ischemic site status

Day 0

Day 180

Day 0

Day 180

Day 0

Day 180

Day 0

Day 180

Day 0

Day 180

1

Low

400

2000

8

0

Right: 1.57

1.56

12

24

Toe gangrene (amputated) surgery

Well improved

Left: 1.09

1.09

2

Low

200

700

7

1

Right: 0.8

1.22

11

20

Toe necrosis/history of minor amputation

Minor amputation, well improved

Left: 0.7

1.21

3

Low

N/A

N/A

9

0

1.13

1.43

10

19

Non-healing ulcers

Ulcer healing, well improved

4

High

300

1500

8

1

1.25

1.16

12

22

Extensive gangrene with impending amputation/history of minor amputation

Minor amputation (day 30), well improved

5

High

N/A

N/A

9

N/A

0.78

N/A

9

N/A

Extensive gangrene with impending amputation

Major amputation (day 70)

6

High

10

10

9

2

0.87

0.92

9

20

Extensive gangrene with impending amputation

Minor amputation (day 90), well improved

7

High

0

100

8

2

1.16

0.8

11

19

Extensive gangrene with impending amputation

Minor amputation (day 40), well improved

8

High

200

1000

7

1

1.17

1.3

13

20

Non-healing ulcer

No change

9

High

250

1000

8

2

0.98

1.21

15

23

Non-healing ulcers at dorsum of the foot/gangrenous toes

Ulcer healing, No change